Blog

Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin

Nov 9 • 2 min read

-Beckley Psytech, a clinical-stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, today announced that the first participant has been dosed in its Phase I clinical trial (NCT05434156) of ELE-101, a novel, short-acting psychedelic compound which is intended to serve as a possible treatment for depression. The trial is…

PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA

Nov 9 • 2 min read

PharmAla Biotech (CSE:MDMA) is pleased to announce that it has submitted its pre-IND data meeting package to the US Food and Drug Administration in advance of its pre-IND meeting scheduled for later this month. PharmAla will be requesting FDA feedback on the nonclinical and CMC development plan to support the initial clinical trial for ALA-002….

Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video

Nov 9 • 1 min read

Algernon Pharmaceuticals (CSE: AGN | OTCQB: AGNPF) – The company is focused on the disease area of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease. Algernon was recently granted permission to conduct a Phase 1 clinical study of DMT for the treatment of stroke. Watch the Video here. About CEO Clips: CEO Clips –…

Universal Ibogaine Announces Formation of Advisory Board

Nov 8 • 4 min read

Universal Ibogaine Inc. (TSXV:IBO), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, is pleased to announce the formation of an external Advisory Board as part of its strategic plans and mission to deliver medicalized ibogaine-centered addiction care and to undertake a planned clinical trial application process. The UI Advisory Board is intended to allow…

George Tziras, CEO of Small Pharma, Sits in the Investor Hotseat on November 10th

Nov 8 • 2 min read

Small Pharma ($TSXV:DMT) CEO, George Tziras, joins the Investor Hotseat to field hot questions from host, Dustin Robinson of Iter Investments. George initially joined Small Pharma in 2015 as a director before being appointed to the role of Chief Business Officer and director of the Company in 2021. He was appointed as CEO in July…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554